Developer docs
API playgroundTry for free, no card

Search company profiles

LexaGene Holdings

Full company profile

uuid0006m9k

Namestring
LexaGene Holdings
Legal namestring
LEXAGENE
Websiteurl
lexagene.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

LexaGene Holdings is a publicly traded molecular diagnostics company founded in 2016 and headquartered in Beverly, Massachusetts, listed on the OTCQB under the symbol LXXGF. The company's stated focus is developing a detection system for pathogens and other molecular markers, positioning it within the veterinary and clinical point-of-care diagnostics segment. According to available firmographic data, the company operates with a very small team of 1-10 employees and has a single documented capital raise of approximately $5.07 million recorded in October 2019, with investors and lead placement undisclosed.

Details on the underlying platform architecture, specific product configurations, validation status, regulatory clearances, and customer adoption are not present in the aggregated source material. The company's web domain (lexagene.com) currently resolves to unrelated Indonesian-language health and gambling content rather than corporate or product material, which raises questions about active digital/operational status and limits the ability to verify current productization, pricing, and customer relationships from the public surface. No management team, board composition, named customers, partnership agreements, patents, certifications, or revenue disclosures are available in the input data.

Short descriptiontext

LexaGene Holdings is a publicly traded molecular diagnostics company developing pathogen and molecular marker detection systems, headquartered in Beverly, Massachusetts, operating with a small team of under ten employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBeverly, United States
HQ citystring
Beverly
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
molecular diagnostics, pathogen detection systems, infectious disease testing, PCR-based diagnostics, veterinary diagnostics
Industry3 codes
1SaMD – Imaging & Signal Analysis (AI/ML)
CodeHLACANAGPrimaryYes
2SaMD – Digital Biomarkers & Algorithmic Endpoints
CodeHLACANAFPrimaryNo
3Companion Diagnostics (CDx) Development & Trial Testing Support
CodeHLAGAEAJPrimaryNo
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics Instruments
Social media profiles2 records
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

LexaGene Holdings is a molecular diagnostics company that develops a system for the detection of pathogens and other molecular markers. The company's technology is designed to deliver rapid, automated molecular testing for applications in human and veterinary diagnostics, enabling identification of infectious agents and biomarkers at the point of need.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

The source data from lexagene.com does not contain information about LexaGene Holdings Inc. (the biotech company). The domain lexagene.com is described as an Indonesian health news portal covering topics such as diet, parenting, health, and diseases. The content primarily discusses online gambling platforms (Osaka88, Tangandewa, Texas88, Hoki22, Sbobet, Gudangtoto, and various slot games), which are unrelated to a biotech company's product portfolio.

Product and service1 record
1Pathogen and Molecular Marker Detection System
CategoryMolecular Diagnostics Instruments
Description

An automated molecular diagnostics system designed for the detection of pathogens and other molecular markers, intended for use by veterinary clinics, diagnostic laboratories, and other institutional customers requiring rapid molecular testing.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
1Accelerate Diagnostics
TypeDirect peer
Description

Accelerate Diagnostics develops rapid identification and antimicrobial susceptibility testing platforms for serious infectious disease pathogens. Comparable as a small-cap, instrument-based molecular/microbial diagnostics company targeting clinical pathogen detection.

2Hologic
TypeBroad incumbent
Description

Hologic's Panther and Panther Fusion systems are widely deployed molecular diagnostics instruments for infectious disease testing. Comparable in target customer (clinical labs) and application (molecular pathogen detection), though Hologic is a much broader women's-health and diagnostics incumbent.

3BioFire Diagnostics (bioMérieux)
TypeBroad incumbent
Description

BioFire's FilmArray system is the leading syndromic molecular pathogen-detection platform used in clinical and applied markets. It is directly comparable to LexaGene's stated pathogen-detection system in terms of end-user workflow and target pathogens, but operates at vastly greater scale as part of bioMérieux.

4GenMark Diagnostics (Roche)
TypeDirect peer
Description

GenMark's ePlex system delivers syndromic molecular pathogen detection from a compact benchtop instrument. Closely comparable to LexaGene's benchtop pathogen-detection concept in form factor and clinical use case.

5T2 Biosystems
TypeDirect peer
Description

T2 Biosystems develops small-footprint molecular diagnostics instruments (T2Dx, T2Bacteria, T2Candida) targeting rapid pathogen detection. Closely comparable to LexaGene as a small, focused molecular diagnostics instrumentation company competing with much larger incumbents.

6Thermo Fisher Scientific
TypeBroad incumbent
Description

Thermo Fisher sells Applied Biosystems real-time PCR instruments and reagent kits used for pathogen detection in clinical, veterinary, and food-safety labs. Comparable in underlying molecular detection technology, though as a much broader life-sciences tools incumbent.

7QIAGEN
TypeBroad incumbent
Description

QIAGEN supplies sample-prep and PCR-based molecular diagnostics solutions for pathogen detection across human and veterinary markets. Comparable technology stack (molecular sample-to-answer) and overlapping customer base, with significantly broader product portfolio.

8Meridian Bioscience
TypeDirect peer
Description

Meridian develops and commercializes molecular diagnostic test kits and instruments (including the Revogene system) for infectious disease detection. Comparable to LexaGene as a smaller, focused molecular pathogen-detection business operating alongside larger incumbents.

9Cepheid (Danaher)
TypeBroad incumbent
Description

Cepheid's GeneXpert is the dominant cartridge-based molecular diagnostics platform for pathogen detection across clinical, veterinary, and applied markets. Comparable to LexaGene in target application (rapid molecular pathogen detection) but with much broader installed base and cleared menu.

10OpGen
TypeDirect peer
Description

OpGen (which absorbed Curetis) markets molecular microbiology and rapid pathogen-ID workflows (Unyvero, ARES) for hospital infection control. Comparable to LexaGene as a small-cap, molecular pathogen-detection company focused on clinical and applied microbiology customers.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LexaGene Holdings

Molecular Diagnostics Instrumentslexagene.com

LexaGene Holdings is a publicly traded molecular diagnostics company developing pathogen and molecular marker detection systems, headquartered in Beverly, Massachusetts, operating with a small team of under ten employees.

What LexaGene Holdings does

LexaGene Holdings is a publicly traded molecular diagnostics company founded in 2016 and headquartered in Beverly, Massachusetts, listed on the OTCQB under the symbol LXXGF. The company's stated focus is developing a detection system for pathogens and other molecular markers, positioning it within the veterinary and clinical point-of-care diagnostics segment. According to available firmographic data, the company operates with a very small team of 1-10 employees and has a single documented capital raise of approximately $5.07 million recorded in October 2019, with investors and lead placement undisclosed.

Details on the underlying platform architecture, specific product configurations, validation status, regulatory clearances, and customer adoption are not present in the aggregated source material. The company's web domain (lexagene.com) currently resolves to unrelated Indonesian-language health and gambling content rather than corporate or product material, which raises questions about active digital/operational status and limits the ability to verify current productization, pricing, and customer relationships from the public surface. No management team, board composition, named customers, partnership agreements, patents, certifications, or revenue disclosures are available in the input data.

LexaGene Holdings firmographics

Firmographics
Name
LexaGene Holdings
Legal name
LEXAGENE
Website
https://lexagene.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
LexaGene Holdings is a publicly traded molecular diagnostics company developing pathogen and molecular marker detection systems, headquartered in Beverly, Massachusetts, operating with a small team of under ten employees.
Ownership category
akta.pro rank

LexaGene Holdings industry classification

Industry
Product category
Molecular Diagnostics Instruments
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry
SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
akta.pro secondary industries
SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ)

Keywords

  • Molecular diagnostics
  • Pathogen detection systems
  • Infectious disease testing
  • PCR-based diagnostics
  • Veterinary diagnostics

Where LexaGene Holdings is headquartered

Location

Headquarters

HQ city
Beverly
HQ country
United States
HQ region
North America

Markets served

LexaGene Holdings business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Marketing channels1 record

LexaGene Holdings product offering

Product offering

Core offering

LexaGene Holdings is a molecular diagnostics company that develops a system for the detection of pathogens and other molecular markers. The company's technology is designed to deliver rapid, automated molecular testing for applications in human and veterinary diagnostics, enabling identification of infectious agents and biomarkers at the point of need.

Product overview

The source data from lexagene.com does not contain information about LexaGene Holdings Inc. (the biotech company). The domain lexagene.com is described as an Indonesian health news portal covering topics such as diet, parenting, health, and diseases. The content primarily discusses online gambling platforms (Osaka88, Tangandewa, Texas88, Hoki22, Sbobet, Gudangtoto, and various slot games), which are unrelated to a biotech company's product portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pathogen and Molecular Marker Detection System An automated molecular diagnostics system designed for the detection of pathogens and other molecular markers, intended for use by veterinary clinics, diagnostic laboratories, and other institutional customers requiring rapid molecular testing.

Companies that use LexaGene Holdings

Customer profile

Ideal customer profiles1 record

LexaGene Holdings technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LexaGene Holdings partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

LexaGene Holdings competitors and assessment

Company assessment

Direct peers

  • Accelerate Diagnostics: Accelerate Diagnostics develops rapid identification and antimicrobial susceptibility testing platforms for serious infectious disease pathogens. Comparable as a small-cap, instrument-based molecular/microbial diagnostics company targeting clinical pathogen detection.
  • GenMark Diagnostics (Roche): GenMark's ePlex system delivers syndromic molecular pathogen detection from a compact benchtop instrument. Closely comparable to LexaGene's benchtop pathogen-detection concept in form factor and clinical use case.
  • T2 Biosystems: T2 Biosystems develops small-footprint molecular diagnostics instruments (T2Dx, T2Bacteria, T2Candida) targeting rapid pathogen detection. Closely comparable to LexaGene as a small, focused molecular diagnostics instrumentation company competing with much larger incumbents.
  • Meridian Bioscience: Meridian develops and commercializes molecular diagnostic test kits and instruments (including the Revogene system) for infectious disease detection. Comparable to LexaGene as a smaller, focused molecular pathogen-detection business operating alongside larger incumbents.
  • OpGen: OpGen (which absorbed Curetis) markets molecular microbiology and rapid pathogen-ID workflows (Unyvero, ARES) for hospital infection control. Comparable to LexaGene as a small-cap, molecular pathogen-detection company focused on clinical and applied microbiology customers.

Broad incumbents

  • Hologic: Hologic's Panther and Panther Fusion systems are widely deployed molecular diagnostics instruments for infectious disease testing. Comparable in target customer (clinical labs) and application (molecular pathogen detection), though Hologic is a much broader women's-health and diagnostics incumbent.
  • BioFire Diagnostics (bioMérieux): BioFire's FilmArray system is the leading syndromic molecular pathogen-detection platform used in clinical and applied markets. It is directly comparable to LexaGene's stated pathogen-detection system in terms of end-user workflow and target pathogens, but operates at vastly greater scale as part of bioMérieux.
  • Thermo Fisher Scientific: Thermo Fisher sells Applied Biosystems real-time PCR instruments and reagent kits used for pathogen detection in clinical, veterinary, and food-safety labs. Comparable in underlying molecular detection technology, though as a much broader life-sciences tools incumbent.
  • QIAGEN: QIAGEN supplies sample-prep and PCR-based molecular diagnostics solutions for pathogen detection across human and veterinary markets. Comparable technology stack (molecular sample-to-answer) and overlapping customer base, with significantly broader product portfolio.
  • Cepheid (Danaher): Cepheid's GeneXpert is the dominant cartridge-based molecular diagnostics platform for pathogen detection across clinical, veterinary, and applied markets. Comparable to LexaGene in target application (rapid molecular pathogen detection) but with much broader installed base and cleared menu.

Market position

Strengths2 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights3 records

Customer concentration

LexaGene Holdings social profiles

Digital presence

LexaGene Holdings financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LexaGene Holdings leadership team

Management profile

Number of profiles

LexaGene Holdings funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LexaGene Holdings M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LexaGene Holdings

What does LexaGene Holdings do?

LexaGene Holdings is a molecular diagnostics company that develops a system for the detection of pathogens and other molecular markers. The company's technology is designed to deliver rapid, automated molecular testing for applications in human and veterinary diagnostics, enabling identification of infectious agents and biomarkers at the point of need.

Is LexaGene Holdings a public or private company?

LexaGene Holdings is a private company. It is classified as public and is currently operating.

When was LexaGene Holdings founded?

LexaGene Holdings was founded in 2016. It employs 1 to 10 people.

Where is LexaGene Holdings based?

LexaGene Holdings is headquartered in Beverly, United States, in the North America region.

Who are LexaGene Holdings's main competitors?

Direct peers on record are Accelerate Diagnostics, GenMark Diagnostics (Roche), T2 Biosystems, Meridian Bioscience and OpGen. Broad incumbents are Hologic, BioFire Diagnostics (bioMérieux), Thermo Fisher Scientific, QIAGEN and Cepheid (Danaher).

Does LexaGene Holdings have an API?

No public API is recorded for LexaGene Holdings.

What industry is LexaGene Holdings in?

LexaGene Holdings's product category is Molecular Diagnostics Instruments. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireLexaGene Adopts Corporate Governance Charters and PoliciesLexaGene Holdings adopted new corporate governance charters and policies, including audit, compensation, and nominating charters, plus a cyber security policy and code of conduct. The company also filed a shelf prospectus allowing it to offer up to $25 million in securities over 25 months.PR NewswireAmericans Are Spending More Than Ever on Pets, Sending the Entire Industry to New HighsAmerican pet spending has more than doubled over the last decade, reaching $103.6 billion in 2020, as millennials drive increased expenditure on pet food, grooming, vet care, insurance, and subscription services. LexaGene Holdings Inc. announced two purchase orders for its MiQLab veterinary diagnostic system from Denver Animal Emergency and Alpine Veterinary Hospital, following the expansion of its sales team and attendance at the ACVIM Forum, while also partnering with Ethos Discovery to expand test menu offerings. Additional pet sector companies including The Original Bark Co., Petmed Express Inc., Zoetis Inc., and Aon PLC reported positive metrics, with the pet care market projected to grow significantly in the coming years.PR NewswireSocial Distancing Creates Pet-buying Boom that Sends the Industry to New HeightsThe COVID-19 pandemic drove a surge in pet adoptions, with approximately 85 million families in the US now owning pets, creating significant demand for pet care products and services. Companies including LexaGene Holdings, Chewy, Zomedica Pharmaceuticals, Elanco Animal Health, and Petco Health and Wellness have responded with new offerings, including LexaGene's MiQLab molecular diagnostic system for veterinary clinics, which provides pathogen detection results within two hours. The article notes that veterinary costs represent a significant ongoing expense for pet owners, with dog owners spending up to $1,201 annually and cat owners up to $687 annually on average.PR NewswireWhy There's Still Need for Rapid Accessible Pathogen Testing, During and After the CrisisOn December 30th, LexaGene Holdings Inc. announced it has begun FDA studies required for Emergency Use Authorization of its MiQLab automated pathogen detection system for COVID-19 testing at point-of-care settings, positioning the technology as uniquely accessible for non-technical users. The article discusses how the pandemic has accelerated development of rapid pathogen testing technologies across multiple companies, including Medmira's improved antibody test, Co-Diagnostics' Logix Smart COVID-19 test kit, 3M's antigen test collaboration with MIT, and Abbott's BinaxNOW rapid test. These technologies are described as having applications beyond the current crisis, including food safety, veterinary diagnostics, and early detection capabilities for future health threats.GlobeNewswireLexaGene to Participate at the 13th Annual LD Micro Main Event ConferenceLexaGene Holdings CEO Dr. Jack Regan will present at the 13th Annual LD Micro Main Event Conference on December 15, 2020. The company also engaged Native Ads, Inc. for a 12-month digital marketing campaign starting January 2021, with services valued at $150,000.GlobeNewswireTesting’s Critical Role in Stemming the TideLexaGene Holdings announced its placement in a NetworkNewsWire editorial on pathogen detection. The company's automated genetic analyzer can identify 27 pathogens in about an hour and is working with the FDA on an Emergency Use Authorization for COVID-19 testing.PR NewswireBreakthroughs and Advancements in Pathogen Detection Offer Hope as Virus Cases SurgeUS coronavirus cases exceeded 3 million with estimates of 10 times more, highlighting urgent demand for faster, more accurate testing as public health experts stress early detection is paramount to controlling spread. Massachusetts-based LexaGene Holdings Inc. has developed the MiQLab automated genetic analyzer that can detect up to 27 pathogens including COVID-19 in approximately one hour and has placed a pre-commercial instrument at Dartmouth-Hitchcock Medical Center in New Hampshire while awaiting FDA Emergency Use Authorization. The article also profiles several other companies actively involved in COVID-19 response including Roche (antibody tests), Hologic (genetic testing), Vaxart (oral vaccine), and Gilead (remdesivir therapeutic).PR NewswireSecond Wave Concerns Create Urgent Need For Fast, Accurate Tests and Plausible VaccinesAs WHO warns that lifting public health restrictions too early could trigger a second COVID-19 peak, multiple biotechnology companies are advancing rapid testing and vaccine candidates to support economic reopening. LexaGene Holdings placed its pre-commercial genetic analyzer at Dartmouth-Hitchcock Medical Center, Co-Diagnostics received FDA Emergency Use Authorization and manufactured over six million tests, Moderna secured Fast Track designation for its vaccine candidate mRNA-1273, and Sorrento Therapeutics reported 100% in vitro inhibition of the virus with its antibody STI-1499. Abbott Labs' ID NOW rapid test is under scrutiny for potential accuracy concerns despite shipping over two million units.GlobeNewswireLexaGene Holdings Proposes to Amend Warrants Terms and Announces a Strategic Marketing Promotional CampaignLexaGene Holdings proposed to amend its March 2019 warrants, reducing the exercise price from $0.85 to $0.60 per share. The company also announced a strategic marketing campaign with Native Ads, Inc., scheduled to begin in May and continue until $150,000 in services are rendered.GlobeNewswireLexaGene Files Three Additional US Patents Covering TechnologyLexaGene Holdings filed three additional US patents covering its LX2 genetic analyzer technology, including sample prep DNA extraction, data processing, and microfluidic PCR functions. The patents add to the company's intellectual property portfolio, which the CEO says protects its low-cost, rapid testing platform.